VRC01LS

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionHIV Infections

Phase 1

Evaluating the Safety and Pharmacokinetics of VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants

CompletedNCT02256631

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2015-06-30End: 2021-12-16Updated: 2023-02-08

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

CompletedNCT02797171

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2017-03-01End: 2019-06-05Updated: 2024-03-20

Dual bNAb Treatment in Children

CompletedNCT03707977

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infection

Start: 2019-06-17End: 2021-12-03Updated: 2025-05-14

Related Papers

Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study

Clinical Infectious Diseases2025-10-09

Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection

JCI Insight2025-02-235 citations

Caregivers of children with HIV in Botswana prefer monthly IV Broadly Neutralizing Antibodies (bNAbs) to daily oral ART

PLoS ONE2024-03-274 citations

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

PLoS Medicine2018-01-24249 citations